These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 4630916)

  • 21. L-dopa for parkinsonism.
    Reveno WS; Bauer RB; Rosenbaum H
    Geriatrics; 1973 Jan; 28(1):86-8. PubMed ID: 4683093
    [No Abstract]   [Full Text] [Related]  

  • 22. [Clinical experience with L-DOPA in the treatment of parkinsonism].
    Chiba T
    No To Shinkei; 1970 Dec; 22(12):1399-405. PubMed ID: 5536833
    [No Abstract]   [Full Text] [Related]  

  • 23. [Treatment of Parkinson's disease with L-dopa. 77 cases].
    Boudin G; Castaigne P; Lhermitte F; Beck H; Guillard A; Marteau R; Pepin B; Rondot P; Raphy B
    Rev Neurol (Paris); 1970 Feb; 122(2):89-102. PubMed ID: 4931719
    [No Abstract]   [Full Text] [Related]  

  • 24. L-dopa therapy in Parkinson's disease.
    Lipman IJ
    Va Med Mon (1918); 1971 May; 98(5):242-8. PubMed ID: 4931138
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment of parkinsonism with levo-dopa: results in 302 cases.
    Newkirk TA; Magee KR
    Mich Med; 1971 Sep; 70(22):805-11. PubMed ID: 5141211
    [No Abstract]   [Full Text] [Related]  

  • 26. Combined treatment of parkinsonism with L-dopa and amantadine.
    Godwin-Austen RB; Frears CC; Bergmann S; Parkes JD; Knill-Jones RP
    Lancet; 1970 Aug; 2(7669):383-5. PubMed ID: 4194690
    [No Abstract]   [Full Text] [Related]  

  • 27. [Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor].
    Guillard A
    Brux Med; 1972 Oct; 52(10):673-80. PubMed ID: 4656191
    [No Abstract]   [Full Text] [Related]  

  • 28. [L-Dopa in the treatment of Parkinson's disease. (Considerations on 51 cases)].
    Mazza C; Buffatti PF; Bazzan A; Lion P
    Fracastoro; 1970; 63(5):768-73. PubMed ID: 5519378
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy of and possible differences in tolerance to L-dopa tablets with different rates of release of the active substance.
    Völler GW; Muschard F
    Acta Neurol Scand; 1974; 50(3):391-3. PubMed ID: 4525037
    [No Abstract]   [Full Text] [Related]  

  • 30. L-Dopa (L-3,4-dihydroxyphenylanine)--its clinical effects in parkinsonism.
    Yahr MD; Duvoisin RC; Hoehn MM; Schear MJ; Barrett RE
    Trans Am Neurol Assoc; 1968; 93():56-63. PubMed ID: 4885744
    [No Abstract]   [Full Text] [Related]  

  • 31. [L-dopa and parkinsonism. A preliminary report].
    Pakkenberg H
    Ugeskr Laeger; 1969 May; 131(22):959-60. PubMed ID: 5793628
    [No Abstract]   [Full Text] [Related]  

  • 32. [Mental disorders in the course of L-dopa treatment].
    Reichowa J; Goldsztajn M
    Psychiatr Pol; 1973; 7(1):87-9. PubMed ID: 4715838
    [No Abstract]   [Full Text] [Related]  

  • 33. [Advances in the treatment of parkinsonism].
    Dowzenko A
    Neurol Neurochir Pol; 1972; 6(2):275-80. PubMed ID: 4555308
    [No Abstract]   [Full Text] [Related]  

  • 34. [Treatment of Parkinsonism with L-dopa--with special reference to clinical effects, side effects and urinary metabolites of catecholamines].
    Uono M; Tanabe H; Yano Y; Nakao K
    No To Shinkei; 1970 Sep; 22(9):1091-101. PubMed ID: 5536082
    [No Abstract]   [Full Text] [Related]  

  • 35. [L-dopa and Parkinson's disease].
    Barbeau A
    Union Med Can; 1970 Dec; 99(12):2195-7. PubMed ID: 5488646
    [No Abstract]   [Full Text] [Related]  

  • 36. L-dopa in the treatment of parkinsonism.
    Haleem MA
    Gerontol Clin (Basel); 1972; 14(4):242-8. PubMed ID: 4634915
    [No Abstract]   [Full Text] [Related]  

  • 37. Improvement in mono-manual dexterity in parkinsonism when supplementing levodopa with an extracerebral decarboxylase inhibitor, RO 4-4602.
    Knutsson E; Mårtensson A
    Scand J Rehabil Med; 1974; 6(2):89-93. PubMed ID: 4837060
    [No Abstract]   [Full Text] [Related]  

  • 38. [Preliminary impressions of the therapeutic effectiveness of L-dopa in Parkinson's disease].
    Buscaino GA; Campanella G
    Sist Nerv; 1970; 22(2):82-91. PubMed ID: 5504561
    [No Abstract]   [Full Text] [Related]  

  • 39. [Study of L-dopa treatment and its principal side effects in aged subjects].
    Antonini F; Baroni A; Bucalossi A; Roveyaz L
    Gerontol Clin (Basel); 1972; 14(5):297-309. PubMed ID: 4144357
    [No Abstract]   [Full Text] [Related]  

  • 40. [Treatment of parkinsonism with L-dopa].
    Court J; Kase JC; Palacios E; Mena I
    Rev Med Chil; 1971 Jun; 99(6):399-401. PubMed ID: 5561157
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.